Perrigo has appointed an acting CFO and hired a new president for an international business unit.
The Dublin-based drug maker, which has its North American base in Allegan, said yesterday Ron Winowiecki has been named acting CFO, following the previously announced departure of Judy Brown on April 1.
The appointment is effective immediately.
Winowiecki has worked for Perrigo since 2008, most recently as SVP of Business Finances, a position he’s held since 2014.
He’s also served in the roles of VP of Perrigo’s Treasury and Accounting Shared Services and corporate VP and treasurer for the company.
Prior to joining Perrigo, Winowiecki served as CFO for Innotec Company, VP and corporate controller for SPX Corporation and corporate controller and chief accounting officer at Donnelly Corporation.
Winowiecki holds a bachelor’s degree in accounting from Hope College and a master’s degree in finance from Western Michigan University.
John Hendrickson, Perrigo CEO, said he’s confident that “this will be a seamless transition,” and Winowiecki will provide “Perrigo and our financial team with strong leadership.”
Perrigo said it is conducting a search for a permanent CFO, which includes Winowiecki as a “key candidate.”
New EVP and CHCI president
Perrigo also said yesterday Svend Andersen has been named EVP and president of the company’s Consumer Healthcare International, or CHCI, business segment.
He will report directly to Hendrickson and join Perrigo's executive committee.
The CHCI segment comprises the branded consumer health care business and Perrigo's legacy international businesses.
Andersen will be responsible for a portfolio consisting mainly of store brand and branded over-the-counter, or OTC, medicines and products, with annual sales of more than $1 billion and operations across multiple countries.
Most recently, Andersen served as EVP of Europe for LEO-Pharma, where he initiated restructuring efforts for its 35-country European business, designed to introduce a new OTC strategy and country-cluster approach, as well as drive process and governance improvements.
Previously, he led Hospira's Europe, Middle East and Africa business, where he enhanced its go-to-market strategy and drove expansion efforts.
Andersen was also responsible for the western European division's pharmaceuticals, generics, OTC and hospital products businesses while at Actavis and also led Alpharma's Europe, Middle East and Africa businesses prior to its acquisition by Actavis.
Hendrickson said Andersen brings a “track record of commercial execution” in Europe within the consumer, generic and prescription pharmaceuticals industries, including “driving process optimization and ensuring supply chain and value chain alignment.”
“He will continue to focus on building and further innovating our OTC portfolios with the clear goal of enhancing profitability,” Hendrickson said.
Andersen will replace Sharon Kochan, who Hendrickson said has provided leadership to the branded health care team “through a critical period.”
“His efforts to enhance the segment's leadership team, instill process discipline and drive execution have prepared the team to thrive under new leadership,” Hendrickson said.
Hendrickson said Kochan will continue to be a “key executive” at Perrigo and its businesses in Australia and Israel during the transition.
In the unaudited and preliminary 2016 financial results the company released yesterday, Perrigo reported the cancellation of $220 million of unprofitable distribution agreements in the CHCI business.
Hendrickson said he expects “improved profitability in our CHCI segment” for 2017.